|1.||Harrington, Robert A: 14 articles (05/2015 - 12/2002)|
|2.||Lincoff, A Michael: 14 articles (12/2008 - 02/2003)|
|3.||Ohman, E Magnus: 13 articles (12/2010 - 12/2002)|
|4.||De Luca, Giuseppe: 12 articles (07/2015 - 01/2008)|
|5.||Topol, Eric J: 12 articles (06/2006 - 12/2002)|
|6.||Roe, Matthew T: 11 articles (12/2010 - 09/2002)|
|7.||Moliterno, David J: 10 articles (05/2015 - 10/2002)|
|8.||Stone, Gregg W: 10 articles (03/2012 - 11/2003)|
|9.||Kereiakes, Dean J: 10 articles (01/2009 - 07/2002)|
|10.||White, Harvey D: 8 articles (05/2015 - 12/2002)|
11/16/1999 - "During the period of pharmacological treatment, each trial demonstrated a significant reduction in the rate of death or nonfatal myocardial infarction in patients randomized to the GP IIb/IIIa inhibitor compared with placebo. "
02/01/2000 - "The pre-PCI administration of GP IIb/IIIa inhibitors is associated with a significant reduction in peri-procedural complications (-41% relative reduction of death or acute myocardial infarction in the 48 hours after PCI, p < 0.001). "
08/01/2000 - "The administration of GP IIb/IIIa antagonists has been shown to be effective in reducing myocardial infarction and cardial death when given before PTCA. "
04/01/2001 - "Furthermore, recent clinical trials with a small number of patients suggest that GP IIb/IIIa inhibitors in combination with low-dose fibrinolytics are safe and effective for the treatment of ST segment elevation myocardial infarction. "
07/01/2012 - "After first promising trials, GP IIb\IIIa inhibitors (GPI) have been widely used in cath labs for about a decade, significantly improving prognosis for patients with STSegment Elevation Myocardial Infarction (STEMI). "
|2.||Acute Coronary Syndrome
02/01/2009 - "The emergency physicians support early identification of high-risk non-ST-elevation acute coronary syndrome patients and early administration of GP IIb-IIIa inhibitors, which are linked to improved patient outcomes. "
03/01/2000 - "These GP IIb/IIIa antagonists have been shown to be effective in improving outcomes among patients undergoing percutaneous coronary interventions and for the treatment of acute coronary syndromes. "
05/01/1997 - "[Inhibitors of platelet receptors GP IIB/IIIA: a new therapeutic class and its promise in the treatment of acute coronary syndromes]."
02/12/1999 - "The clinical efficacy of GP IIb/IIIa-antagonists for acute percutaneous coronary interventions and in the management of the acute coronary syndrome is established. "
01/01/2008 - "Based on clinical trials, GP IIb/IIIa receptor antagonists have been extensively studied and used in patients with acute coronary syndrome or during percutaneous coronary interventions. "
10/01/2008 - "In our experience, percutaneous coronary intervention has high procedural success in dialysis patients and concomitant use of GP IIb/IIIa inhibitors is not associated with any major bleeding complications, making this a feasible, safe and effective revascularization option for patients on dialysis; however, this merits further study in a randomized prospective trial."
06/01/1999 - "Early clinical studies confirm improved early patency and more rapid electrocardiographic resolution, but increased bleeding complications, with the addition of GP IIb/IIIa antagonists to conventional fibrinolysis. "
10/01/1999 - "Strategies for improved management of bleeding complications in these patients, including the choice of a GP IIb-IIIa inhibitor, are clearly needed and are discussed in detail."
10/01/1999 - "This review summarizes current experience related to bleeding complications with various GP IIb-IIIa inhibitors and suggests strategies for improved management of bleeding in patients receiving these agents."
01/01/2014 - "Recent studies yield conflicting results and registry data have suggested that GP IIb/IIIa inhibitors may cause more bleeding than what trials indicate. "
01/01/2005 - "Our study show that patients with unstable angina had a higher expression GP IIb/IIIa on the platelets membrane and elevated percentage of platelet microparticles confirm platelet activation. "
08/01/2000 - "BRING-UP 1 will be followed by BRING-UP 2, the aim of this latter being to assess the effects of beta-blocker therapy on populations underrepresented in randomized trials, and SET-UP, on the use of GP IIb/IIIa platelet receptor inhibitors in unstable angina. "
12/01/1998 - "Recent large-scale randomized trials have demonstrated the value of GP IIb/IIIa receptor inhibitors in reducing the risk of death and MI in unstable angina/non-Q-wave MI patients receiving pharmacologic management. "
12/01/1998 - "Recent large-scale randomized trials have demonstrated the value of GP IIb/IIIa receptor inhibitors in reducing the risk of death and MI in patients with unstable angina or those with MI with non-Q-wave abnormalities who are receiving pharmacologic management. "
01/01/2005 - "There was no significantly different in platelet GP IIb/IIIa expression after the antiplatelet therapy in patients with unstable angina."
11/01/1999 - "New anti-platelet (GP IIb/IIIa) drugs seem to be very effective in the prevention and treatment of the thrombosis. "
09/01/2003 - "Platelet aggregation, a process mediated by GP IIb-IIIa, is responsible for the occlusive events in thrombosis: indeed, GP IIb-IIIa antagonists are effective in blocking arterial thrombosis. "
02/01/2000 - "This observation may contribute to a greater efficacy of GP-IIb/IIIa inhibitors for the treatment of thrombosis in atherosclerotic patients."
02/01/2002 - "The present study demonstrates that the inhibition of platelet GP Ib function by 6B4-Fab is a powerful intervention to prevent platelet thrombus formation in injured arteries without prolongation of the bleeding time; the latter is in contrast to the result after the inhibition of GP IIb/IIIa. "
01/01/2015 - "Early Gp IIb/IIIa inhibitor use may be considered as upstream therapy especially in high-risk patients, whereas the choice of periprocedural administration may be based on thrombus burden or in case of impaired haemodynamic conditions that may compromise oral drug absorption. "
|5.||Aspirin (Acetylsalicylic Acid)
|6.||Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
|1.||Angioplasty (Angioplasty, Transluminal)